- Home
- AKBA vs PHOS Comparison
AKBA vs PHOS Comparison
Compare AKBA & PHOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKBA | PHOS |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 271.7M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AKBA | PHOS |
|---|---|---|
| Price | $0.57 | $11.76 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 22.8K |
| Earning Date | 11-05-2026 | 11-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $10.82 |
| 52 Week High | $1.84 | $21.30 |
Technical Indicators
Market Signals| Indicator | AKBA | PHOS |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 44.17 |
| Support Level | $0.54 | $10.97 |
| Resistance Level | $1.00 | $13.30 |
| Average True Range (ATR) | 0.07 | 1.14 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 45.81 | 36.02 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
About PHOS First Phosphate Corp. American Depositary Shares
First Phosphate Corp owns and is developing igneous rock phosphate mineral properties in the Saguenay Region of Quebec for the production of phosphoric acid for the production of cathode active material for use in lithium iron phosphate (LPF) batteries for the electric vehicle industry.